Oral Mucositis Therapeutics Pipeline to Witness Many Technological Advancements in the Coming Years

25/gen/2018 09:28:15 P&S research market Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Oral mucositis is the most common complication of chemotherapy in cancer patients.

 

It causes damage to mucosal lining of the mouth which results in formation of ulcers. It can result in several problems that includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk of infection due to open sores in the mucosa. 

 

The research also found that various companies received designations from the USFDA for the development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA granted Fast Track designation to AG013 for the treatment of oral mucositis.

 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oral-mucositis-therapeutics-pipeline-analysis

 

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.

Oral Mucositis Therapeutics Pipeline Analysis

·          By Phase

·         By Target

·         By Route of Administration

·         By Molecule Type

 

·         By Company

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl